Ratings DuPont de Nemours Euronext Paris

Equities

DOWCP

US26614N1028

End-of-day quote Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	-.--%

05-29	UBS Adjusts DuPont de Nemours Price Target to $98 From $93, Maintains Buy Rating	MT
05-28	DuPont's Breakup Plan Holds Logic Amid Disadvantages, BofA Says	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Sales forecast by analysts have been recently revised upwards.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Over the past four months, analysts' average price target has been revised upwards significantly.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.32 times its estimated earnings per share for the ongoing year.
With an enterprise value anticipated at 3.24 times the sales for the current fiscal year, the company turns out to be overvalued.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Over the past twelve months, analysts' opinions have been revised negatively.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Diversified Chemicals

	1st Jan change	Capi.	ESG Refinitiv
DUPONT DE NEMOURS	-.--%	34.35B	-
SHIN-ETSU CHEMICAL CO., LTD.	-1.05%	74.34B	B
BASF SE	-0.76%	46.86B	A-
PIDILITE INDUSTRIES LIMITED	+9.37%	18.1B	B
EASTMAN CHEMICAL COMPANY	+12.81%	11.92B	A-
SYENSQO SA/NV	-3.01%	10.43B	-
BRENNTAG SE	-20.72%	10.33B	B
ASAHI KASEI CORPORATION	-1.35%	9.04B	A-
SRF LIMITED	-11.01%	7.84B	C-
MITSUBISHI CHEMICAL GROUP CORPORATION	-3.85%	7.52B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes